Tom - if Arikace has indeed demonstrated efficacy against NTM Insmed will already have the Non-CF Bronchiectasis opportunity.
Anybody who took the trouble to read the transcript of the FDA-sponsored workshop on the development of antibiotics for that patient population will have read the comments that those patients tend to be colonised with a variety of pathogens.
When a pulmonologist needs to treat a patient with an as-yet diagnosed pneumonia he suspects is caused by pseudomonas he need only argue that he suspects NTM infection in order to engineer approved use of Arikace.
Imo Lewis anticipates much broader use of Arikace than in Non-CF Bronchiectasis.
The Phase 2B trial patients were recalcitrant after 6 months of standard treatment. Lewis said about 5000 NTM patients are in that category. Taking it much, much broader would be first-line treatment for the entire NTM population.